Facebook
Twitter
LinkedIn
ForwardOctober 5, 2023 MGH Cancer Center Grand Rounds 2023-2024: Novel Therapeutics in Gynecologic Cancers - Archive
Description
This activity provides on-demand archived lectures from the MGH Cancer Center Grand Rounds 2023-2024 series. As one of the leading academic cancer centers in the country, our research and clinical staff need to be educated on cutting edge information on advances and perspectives on cancer research and treatment across the full spectrum of cancer specialization. This will help clinicians understand, assess and apply this information in our rapidly advancing and highly specialized organization. Clinicians will present and discuss this information in a multi-specialty setting. Clinicians will be informed and challenged across the organization to reach beyond their own specialization and role, and support higher levels of learning and competence for themselves, teams, and functions.
The theme of the series is "Women in Cancer: and kicks off Thursday September 7, 2023 at 12:00 PM EDT. with the annual "Chabner Pioneers in Oncology Lectureship". The series will cover a comprehensive array of disease areas and topics, attendees will be provided with a robust selection of sessions to bring them up to speed on the most cutting-edge research and therapies in oncology.
All sessions will allow live attendees the opportunity to interact with the presenters and ask questions, thus supporting active learning
Course Director: Colin D. Weekes, MD, PhD
For questions regarding the registration process, please contact Mass General Brigham Office of Continuing Professional Development at partnerscpd@partners.org.
You may print individual certificates throughout the year; your cumulative list of sessions attended is accessible on your transcript.
This session is available outside of Mass General Brigham
Target Audience
This activity is intended for research and clinical staff who need to be educated on cutting edge information on advances and perspectives on cancer research and treatment across the full spectrum of cancer specialization.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Evaluate recent advances or controversies in hematology/oncology treatment, clinical research and/or basic science investigation presented in this series
- Assess opportunities to integrate information, tools or practices presented in this conference into how you deliver or support research and patient care
- Apply new information or perspectives from this conference into specific aspects of your responsibilities in patient care, research or the system in which you work.
- Recognize evolving landscape of cancer care worldwide
Additional Information
| Attachment | Size |
|---|---|
 2023-10-05 Disclosure Summary Slides.pptx | 48.07 KB |
Mass General Brigham
Course Directors
Colin D. Weekes, MD, PhD
Director, Pancreatic Cancer Research,
Mass General Cancer Center;
Associate Professor of Medicine,
Harvard Medical School
Faculty/Speakers
Roisin O’Cearbhaill, MD
Memorial Sloan-Kettering Cancer Center
DISCLOSURE SUMMARY OF RELEVANT FINANCIAL RELATIONSHIPS
MITIGATION STRATEGIES
Mass General Brigham has implemented a process to mitigate relevant financial relationships for this continuing education (CE) activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public.
The following planners reported no relevant financial relationship with an ineligible company:
Kellyann Jeffries, CNP
The following planners reported a relevant financial relationship with an ineligible company:
Colin D. Weekes, MD, PhD
Consultant: Ipsen, Genentech, Actuate Therapeutics
Research Funding: Novartis, Genentech, Actuate Therapeutics, Elicio Therapeutics, OncoC4, Deciphera Pharmaceuticals
Scientific Advisory Board: VRise Therapeutics
Kerry Reynolds
Advisory Board: SAGA Diagnostics
Public Stock: Biogen (ended)
Priscilla Brastianos, MD
Consultant/Advisor: Kazia
Clinical trial support: AstraZeneca, Eli Lily, Mirati, Merck, BMS, Kazia, Genentech Roche, Pfizer, GSK
Institutional Research Support: Eli Lilly, Kinnate BioPharma, Mirati Therapeutics, Merck
Consulting Fees: MPM, CraniUS, In Cephalo, Axiom
The following speakers reported no relevant financial relationship with an ineligible company:
The following speakers reported a relevant financial relationship with an ineligible company:
Roisin O’Cearbhaill, MD
Advisory Board: Tesaro/GSK, Regeneron, SeaGen, 2seventybio, Miltenyibio
Meal: Immunogen
Meeting Travel: Gathering Around Cancer (Ireland)
Clinical Trial Research Grants: Bayer/Celgene/Juno, Tesaro/GSK, Merck, Ludwig Cancer Institute, Abbvie/StemCentrx, Regeneron, TCR2 Therapeutics, Atara Biotherapeutics, Marker Therapeutics, Syndax Pharmaceuticals, Genmab/Seagen Therapeutics, Genentech, Alkermes, Kite Pharma, Acrivon, Arsenalobio and Gynecologic Oncology Foundation, Lyell Immunopharma
ACCREDITATION
In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AMA PRA Category 1 CreditTM
Mass General Brigham designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing
Mass General Brigham designates this activity for 1 ANCC contact hour. Nurses should only claim credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Nursing Contact Hours
- 1.00 Participation